# Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients

> **NCT02498535** · PHASE2 · TERMINATED · sponsor: **Novoteris, LLC** · enrollment: 49 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Nitric Oxide 160 ppm

## Key facts

- **NCT ID:** NCT02498535
- **Lead sponsor:** Novoteris, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-22
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Terminated for the safety of cystic fibrosis clinical trial subjects due to Covid-19.
- **Last updated:** 2021-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02498535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02498535, "Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02498535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*